8HUD image
Deposition Date 2022-12-23
Release Date 2023-12-27
Last Version Date 2024-10-09
Entry Detail
PDB ID:
8HUD
Title:
Cryo-EM structure of the EvCas9-sgRNA-target DNA ternary complex
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.43 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:CRISPR-associated endonuclease Cas9
Gene (Uniprot):csn1
Chain IDs:A
Chain Length:1107
Number of Molecules:1
Biological Source:Eubacterium ventriosum ATCC 27560
Polymer Type:polyribonucleotide
Molecule:sgRNA
Chain IDs:B
Chain Length:75
Number of Molecules:1
Biological Source:synthetic construct
Polymer Type:polydeoxyribonucleotide
Molecule:Target DNA strand
Chain IDs:C
Chain Length:28
Number of Molecules:1
Biological Source:synthetic construct
Polymer Type:polydeoxyribonucleotide
Molecule:Non-target DNA strand
Chain IDs:D
Chain Length:8
Number of Molecules:1
Biological Source:synthetic construct
Ligand Molecules
Primary Citation
Molecular Basis and Genome Editing Applications of a Compact Eubacterium ventriosum CRISPR-Cas9 System.
Acs Synth Biol 13 269 281 (2024)
PMID: 38061052 DOI: 10.1021/acssynbio.3c00501

Abstact

CRISPR-Cas9 systems have been widely harnessed for diverse genome editing applications because of their ease of use and high efficiency. However, the large molecular sizes and strict PAM requirements of commonly used CRISPR-Cas9 systems restrict their broad applications in therapeutics. Here, we report the molecular basis and genome editing applications of a novel compact type II-A Eubacterium ventriosum CRISPR-Cas9 system (EvCas9) with 1107 residues and distinct 5'-NNGDGN-3' (where D represents A, T, or G) PAM specificity. We determine the cryo-EM structure of EvCas9 in a complex with an sgRNA and a target DNA, revealing the detailed PAM recognition and sgRNA and target DNA association mechanisms. Additionally, we demonstrate the robust genome editing capacity of EvCas9 in bacteria and human cells with superior fidelity compared to SaCas9 and SpCas9, and we engineer it to be efficient base editors by fusing a cytidine or adenosine deaminase. Collectively, our results facilitate further understanding of CRISPR-Cas9 working mechanisms and expand the compact CRISPR-Cas9 toolbox.

Legend

Protein

Chemical

Disease

Primary Citation of related structures